A carregar...
Publicação
O papel das vesículas extracelulares na resistência ao tratamento do cancro da cabeça e pescoço : uma revisão sistemática
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 544.04 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
O cancro da cabeça e pescoço constitui um importante problema de saúde pública, representando uma das neoplasias mais frequentes a nível mundial. Apesar dos avanços registados nas abordagens terapêuticas, incluindo cirurgia, radioterapia, quimioterapia, imunoterapia e terapia dirigida, a resistência continua a ser uma das principais causas de insucesso no tratamento, levando à diminuição da sobrevivência dos pacientes. Neste contexto, as vesículas extracelulares (EVs) têm emergido como potenciais biomarcadores minimamente invasivos, capazes de refletir alterações moleculares associadas à progressão tumoral e à resposta ao tratamento. O presente trabalho teve como objetivo explorar o papel das EVs como ferramenta para a monitorização da resistência ao tratamento do cancro da cabeça e pescoço. A revisão foi conduzida segundo as diretrizes PRISMA. A pesquisa bibliográfica foi efetuada nas bases de dados PubMed, Web of Science e Scopus. O processo de seleção dos estudos seguiu critérios de inclusão e exclusão previamente definidos, com triagem independente por dois revisores e resolução de conflitos por um terceiro. Utilizou-se a plataforma Rayyan para a gestão dos artigos. Inicialmente foram identificadas 1254 publicações. Após eliminação dos duplicados e seleção por leitura do título e do resumo, foram excluídos 932 artigos. Após leitura do texto, foram identificados 8 estudos no final. <br/>Os resultados do presente trabalho demonstraram que alterações no conteúdo molecular das EVs estão associadas ao desenvolvimento de resistência ao tratamento, progressão tumoral e recidiva do cancro da cabeça e pescoço. Foi possível identificar biomarcadores associados a EVs com potencial na monitorização da resposta ao tratamento: miR-30a, miR-146a, miR-183-5p e miR-106a-5p, circMYC, PD-L1 e proteínas relacionadas com a transição epitélio-mesenquimal. Em conclusão, o presente trabalho sugere que as EVs têm potencial como biomarcadores não invasivos para a monitorização da resposta ao tratamento. Contudo, são necessários estudos clínicos robustos que permitam comprovar a sua aplicação na prática clínica e consolidar o seu papel na medicina de precisão.
Head and neck cancer is a major public health problem, representing one of the most frequent neoplasms worldwide. Despite advances in therapeutic approaches, including surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy, resistance remains a major cause of treatment failure, leading to decreased patient survival. In this context, extracellular vesicles (EVs) have emerged as potential minimally invasive biomarkers capable of reflecting molecular changes associated with tumor progression and treatment response. This study aimed to explore the role of EVs as a tool for monitoring treatment resistance in head and neck cancer. The review was conducted according to PRISMA guidelines. The bibliographic search was performed in the PubMed, Web of Science, and Scopus databases. The study selection process followed previously defined inclusion and exclusion criteria, with independent screening by two reviewers and conflict resolution by a third. The Rayyan <br/>platform was used for article management. Initially, 1254 publications were identified. After duplicate elimination and selection by reading the title and abstract, 932 articles were excluded. After reading the full-text, 8 studies were identified at the end. The results of this work demonstrated that alterations in the molecular content of EVs are associated with the development of treatment resistance, tumor progression, and recurrence of head and neck cancer. It was possible to identify some biomarkers associated with EVs with potential in monitoring treatment response: miR-30a, miR-146a, miR-183-5p and miR-106a-5p, circMYC, PD-L1 and proteins related to epithelial-mesenchymal transition. In conclusion, this work suggests that EVs have potential as non-invasive biomarkers for monitoring treatment response. However, robust clinical studies are needed to <br/>prove their application in clinical practice and consolidate their role in precision medicine.
Head and neck cancer is a major public health problem, representing one of the most frequent neoplasms worldwide. Despite advances in therapeutic approaches, including surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy, resistance remains a major cause of treatment failure, leading to decreased patient survival. In this context, extracellular vesicles (EVs) have emerged as potential minimally invasive biomarkers capable of reflecting molecular changes associated with tumor progression and treatment response. This study aimed to explore the role of EVs as a tool for monitoring treatment resistance in head and neck cancer. The review was conducted according to PRISMA guidelines. The bibliographic search was performed in the PubMed, Web of Science, and Scopus databases. The study selection process followed previously defined inclusion and exclusion criteria, with independent screening by two reviewers and conflict resolution by a third. The Rayyan <br/>platform was used for article management. Initially, 1254 publications were identified. After duplicate elimination and selection by reading the title and abstract, 932 articles were excluded. After reading the full-text, 8 studies were identified at the end. The results of this work demonstrated that alterations in the molecular content of EVs are associated with the development of treatment resistance, tumor progression, and recurrence of head and neck cancer. It was possible to identify some biomarkers associated with EVs with potential in monitoring treatment response: miR-30a, miR-146a, miR-183-5p and miR-106a-5p, circMYC, PD-L1 and proteins related to epithelial-mesenchymal transition. In conclusion, this work suggests that EVs have potential as non-invasive biomarkers for monitoring treatment response. However, robust clinical studies are needed to <br/>prove their application in clinical practice and consolidate their role in precision medicine.
Descrição
Palavras-chave
Cancro da cabeça e pescoço EVs Biomarcadores Resistência ao tratamento Head and neck cancer Biomarkers Treatment resistance
Contexto Educativo
Citação
Editora
Licença CC
Sem licença CC